Item 2.02 Results of Operations and Financial Condition
On January 9, 2023, MiMedx Group, Inc. (the "Company") issued a press release
and presentation described further in Item 7.01 of this Current Report on
Form 8-K (this "Current Report") reaffirming its fourth quarter of 2022 and full
year 2022 net sales expectations.
Item 7.01 Regulation FD
Beginning on Monday, January 9, 2023, K. Todd Newton, MiMedx interim Chief
Executive Officer, Peter M. Carlson, Chief Financial Officer and Matthew
Notarianni, Head of Investor Relations, are expected to meet with investors and
attend the 41st Annual J.P. Morgan Healthcare Conference on behalf of the
Company. A copy of the presentation materials made available by the Company in
connection with the investor meetings is furnished as Exhibit 99.1 to this
Current Report and is incorporated herein by reference.
In addition, the Company also issued a press release on January 9, 2023,
reaffirming its fourth quarter of 2022 and full year 2022 net sales
expectations, which are also set forth in the presentation. A copy of the press
release is furnished as Exhibit 99.2 to this Current Report and is incorporated
herein by reference.
The information in this Current Report, including Exhibit 99.1 and Exhibit 99.2,
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that section, nor shall such information be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description of Exhibit
99.1 Slide Presentation dated January 9, 2023
99.2 Press release dated January 9. 2023
104 The cover page from this Current Report on Form 8-K, formatted in
Inline XBRL.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses